Mackenzie Financial’s Denali Therapeutics DNLI Stock Holding History

Mackenzie Financial’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,256	Closed	-$240K	–	1722
2024 Q3	$240K	Buy	+8,256	New	+$205K	﹤0.01%	1287
2024 Q2	–	Sell	-10,560	Closed	-$217K	–	1561
2024 Q1	$217K	Buy	+10,560	New	+$198K	﹤0.01%	1308
2023 Q3	–	Sell	-10,465	Closed	-$311K	–	1501
2023 Q2	$311K	Buy	+10,465	New	+$294K	﹤0.01%	1162
2023 Q1	–	Sell	-7,959	Closed	-$221K	–	1543
2022 Q4	$221K	Buy	7,959 +1,438	+22%	+$42.8K	﹤0.01%	1210
2022 Q3	$200K	Sell	6,521 -377	-5%	-$12.3K	﹤0.01%	1252
2022 Q2	$203K	Buy	+6,898	New	+$181K	﹤0.01%	1281
2022 Q1	–	Sell	-7,331	Closed	-$327K	–	1433
2021 Q4	$327K	Sell	7,331 -143	-2%	-$6.78K	﹤0.01%	1108
2021 Q3	$377K	Buy	7,474 +3,549	+90%	+$200K	﹤0.01%	1050
2021 Q2	$308K	Buy	+3,925	New	+$243K	﹤0.01%	1065

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Mackenzie Financial's DNLI Position: Q4 2024 in Review

Mackenzie Financial sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 8,256 shares — an estimated $240K sold.

Mackenzie Financial first reported a position in DNLI in Q2 2021 and held it in 9 quarters. The position peaked at $377K in Q3 2021. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

Mackenzie Financial reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
Mackenzie Financial sold 8,256 Denali Therapeutics shares in Q4 2024, an estimated $240K.
Mackenzie Financial first reported a position in Denali Therapeutics in Q2 2021 and held it in 9 quarters.
Mackenzie Financial's Denali Therapeutics position peaked at $377K in Q3 2021.
223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on Mackenzie Financial's 13F filing for Q4 2024, filed 14 Feb 2025.